|
2025 Journal Article Phase Ib/IIa dose escalation and expansion study of [ <sup>212</sup> Pb]Pb-ADVC001 in metastatic castration-resistant prostate cancer: TheraPb–phase I/II studyHansen, Aaron Richard, Pattison, David A., Ngai, Stanley, Karmann, Anna, Walker, Amanda J., Campbell, Louise, Brady, Jasmine, Katchel, Loren, Holmes, Ingrid, Rose, Stephen E., Baronet, Meghan C., Kryza, Thomas, Vito, Alyssa, Tieu, William, Kuan, Kevin, Griffiths, Matthew R., O’Mahoney, Eoin, Latter, Melissa, Gan, Chun Loo Loo and Wyld, David (2025). Phase Ib/IIa dose escalation and expansion study of [ 212 Pb]Pb-ADVC001 in metastatic castration-resistant prostate cancer: TheraPb–phase I/II study. Journal of Clinical Oncology, 43 (5_suppl). doi: 10.1200/jco.2025.43.5_suppl.tps275 |
|
2024 Journal Article Patient Reported Outcome Measures in cancer care: a hybrid effectiveness-Implementation trial to optimise Symptom control and health service Experience (PROMISE)–protocol for a randomised controlled trial of electronic self-reporting of symptoms versus usual care during and following treatment in patients with cancerWebb, Penelope M, Brown, Amy, Brown, Bena, Collins, Louisa G, Crawford Williams, Fiona, Doupain, Kerrie, Eastgate, Melissa, Fennelly, Vicki, Girgis, Afaf, Hartel, Gunter, Ladwa, Rahul, Martin, Karen, Mason, Robert, McGuire, Peter, Miller, Elizabeth, O’Brien, Suzanne, Packer, Rebecca, Pinkham, Mark B, Sabesan, Sabe, Sanmugarajah, Jasotha, Slapp, Georgia, Tapsall, Doreen, White, Jeanie, Wishart, Laurelie R, Wyld, David and Chan, Raymond J (2024). Patient Reported Outcome Measures in cancer care: a hybrid effectiveness-Implementation trial to optimise Symptom control and health service Experience (PROMISE)–protocol for a randomised controlled trial of electronic self-reporting of symptoms versus usual care during and following treatment in patients with cancer. BMJ Open, 14 (11) e090836, 1-10. doi: 10.1136/bmjopen-2024-090836 |
|
2024 Journal Article Implementation of Patient-Reported Outcomes in a Medical Oncology Setting (the iPROMOS Study): type II hybrid implementation studyRoberts, Natasha Anne, Pelecanos, Anita, Alexander, Kimberly, Wyld, David and Janda, Monika (2024). Implementation of Patient-Reported Outcomes in a Medical Oncology Setting (the iPROMOS Study): type II hybrid implementation study. Journal of Medical Internet Research, 26 e55841, e55841. doi: 10.2196/55841 |
|
2024 Journal Article Validity of patient-reported outcome measures in evaluating nerve damage following chemotherapyLi, Tiffany, Timmins, Hannah C., Mahfouz, Fawaz M., Trinh, Terry, Mizrahi, David, Horvath, Lisa G., Harrison, Michelle, Grimison, Peter, Friedlander, Michael, Marx, Gavin, Boyle, Frances, Wyld, David, Henderson, Robert, King, Tracy, Baron-Hay, Sally, Kiernan, Matthew C., Rutherford, Claudia, Goldstein, David and Park, Susanna B. (2024). Validity of patient-reported outcome measures in evaluating nerve damage following chemotherapy. JAMA Network Open, 7 (8) e2424139, e2424139. doi: 10.1001/jamanetworkopen.2024.24139 |
|
2024 Conference Publication Identifying optimized assessment of nerve damage during chemotherapyLi, Tiffany, Timmins, Hannah C, Mahfouz, Fawaz Mayez, Mizrahi, David, Horvath, Lisa, Harrison, Michelle L., Grimison, Peter S., Friedlander, Michael, Marx, Gavin M., Boyle, Frances M., Wyld, David, Henderson, Robert, King, Tracy, Baron-Hay, Sally E., Kiernan, Matthew C, Rutherford, Claudia, Goldstein, David and Park, Susanna B (2024). Identifying optimized assessment of nerve damage during chemotherapy. 2024 ASCO Annual Meeting, Chicago, IL United States, 31 May - 4 June 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.16_suppl.12016 |
|
2024 Conference Publication Routine, prospective DPYD genotyping guided dose-individualisation for patients receiving fluoropyrimidines: Implementation, prevalence and patient safety outcomes from a multi-institutional clinical trialNalder, Mark, Kulasegaran, Tivya, Lundie, Ben, Woods, Rick, Eastgate, Melissa A., Wyld, David and Burge, Matthew E. (2024). Routine, prospective DPYD genotyping guided dose-individualisation for patients receiving fluoropyrimidines: Implementation, prevalence and patient safety outcomes from a multi-institutional clinical trial. 2024 ASCO Annual Meeting, Chicago, IL, United States, 31 May–4 June 2024. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2024.42.16_suppl.12121 |
|
2024 Journal Article Corrigendum to: COVID-19 vaccine hesitancy, acceptance and informational needs in an Australian cancer population: a cross-sectional surveyScanlon, Brighid, Wyld, David, Firman, Paul, Nakagaki, Midori, Durham, Jo, Kennedy, Glen, Moran, Paul, Smith, Michael, Button, Elise and Gavin, Nicole (2024). Corrigendum to: COVID-19 vaccine hesitancy, acceptance and informational needs in an Australian cancer population: a cross-sectional survey. Australian Health Review, 48 (3). doi: 10.1071/ah22142_co |
|
2024 Journal Article Exploring unmet needs in prostate cancer care: a cross-sectional descriptive studyRoberts, Natasha A., Esler, Rachel, Pearce, Adam, Wyld, David, Smith, Michael, Woollett, Kaylene, Mazariego, Carolyn and Roberts, Matthew J. (2024). Exploring unmet needs in prostate cancer care: a cross-sectional descriptive study. European Urology Open Science, 62, 36-42. doi: 10.1016/j.euros.2024.01.018 |
|
2024 Conference Publication P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-45 years with intermediate and poor-risk metastatic germ cell tumours (GCTs)Mak, Blossom, Tran, Ben, Pashankar, Farzana D., Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Feldman, Darren R., Dunwoodie, Elaine, Lawrence, Nicola Jane, Birtle, Alison Jane, Wyld, David, Stevanovic, Amanda Gwendolyn, Balagtas, Jay Michael S., Stockler, Martin R., Davis, Ian D. and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2024). P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-45 years with intermediate and poor-risk metastatic germ cell tumours (GCTs). 2024 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 25-27 January 2024. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2024.42.4_suppl.tps524 |
|
2023 Journal Article Cardiac metastases from neuroendocrine neoplasms: complementary role of SSTR PET/CT and cardiac MRIArnfield, Evyn G., Tam, Laura, Pattison, David A., Younger, John, Chikatamarla, Venkata Avinash, Wyld, David, Burge, Matthew, McCormack, Louise, Ladwa, Rahul and Ramsay, Stuart (2023). Cardiac metastases from neuroendocrine neoplasms: complementary role of SSTR PET/CT and cardiac MRI. Journal of Nuclear Cardiology, 30 (6), 2676-2691. doi: 10.1007/s12350-023-03345-w |
|
2023 Journal Article The unmet needs of pancreatic cancer carers are associated with anxiety and depression in patients and carersHuynh, Thi N. T., Hartel, Gunter, Janda, Monika, Wyld, David, Merrett, Neil, Gooden, Helen, Neale, Rachel E. and Beesley, Vanessa L. (2023). The unmet needs of pancreatic cancer carers are associated with anxiety and depression in patients and carers. Cancers, 15 (22) 5307, 1-12. doi: 10.3390/cancers15225307 |
|
2023 Conference Publication Factors that influence clinical trial participation for oncology patients in Australia: A scoping reviewYou, Kyung Ha, Lwin, Zarnie, Ahern, Elizabeth Stephanie, Roberts, Natasha Anne and Wyld, David (2023). Factors that influence clinical trial participation for oncology patients in Australia: A scoping review. 2023 ASCO Quality Care Symposium, Boston, MA United States, 27-28 October 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/op.2023.19.11_suppl.111 |
|
2023 Journal Article The unmet information needs, quality of life, and care experiences of patients with neuroendocrine tumours (NETs) at follow-up: 6 months from diagnosisGuccione, Lisa, Gough, Karla, Drosdowsky, Allison, Price, Timothy, Pavlakis, Nick, Wyld, David, Ransom, David, Michael, Michael and Schofield, Penelope (2023). The unmet information needs, quality of life, and care experiences of patients with neuroendocrine tumours (NETs) at follow-up: 6 months from diagnosis. Supportive Care in Cancer, 31 (10) 577, 1-11. doi: 10.1007/s00520-023-08034-5 |
|
2023 Journal Article Exploring equity in cancer treatment, survivorship, and service utilisation for culturally and linguistically diverse migrant populations living in Queensland, Australia: a retrospective cohort studyScanlon, Brighid, Durham, Jo, Wyld, David, Roberts, Natasha and Toloo, Ghasem Sam (2023). Exploring equity in cancer treatment, survivorship, and service utilisation for culturally and linguistically diverse migrant populations living in Queensland, Australia: a retrospective cohort study. International Journal for Equity in Health, 22 (1) 175, 1-10. doi: 10.1186/s12939-023-01957-9 |
|
2023 Conference Publication An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka Sinikovic, Tran, Ben, Martin, Andrew James, Pashankar, Farzana D., Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Wyld, David, Lawrence, Nicola Jane, Stockler, Martin R., Grimison, Peter S. and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2023). An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs). 2023 ASCO Annual Meeting, Chicago, IL USA, 2-6 June 2023. Alexandria, VA USA: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.16_suppl.tps5102 |
|
2023 Journal Article Investigating the dietary knowledge, attitudes, and beliefs of Australian patients with cancerLee, Shu Fen, Brown, Teresa, Wyld, David, Edwards, Anna and Eastgate, Melissa (2023). Investigating the dietary knowledge, attitudes, and beliefs of Australian patients with cancer. Journal of Human Nutrition and Dietetics, 36 (3), 612-621. doi: 10.1111/jhn.13091 |
|
2023 Conference Publication P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)Zebic, Danka Sinikovic, Ben Tran,, Martin, Andrew James, Pashankar, Farzana D., Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Wyld, David, Lawrence, Nicola Jane, Stockler, Martin R. and Grimison, Peter S. (2023). P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL USA, 2-6 June 2023. Philadelphia, PA USA: Lippincott Williams & Wilkins. |
|
2023 Journal Article Rethinking cancer prevention for migrant populations in Queensland, Australia: A retrospective cohort study comparing culturally and linguistically diverse and Australian born cancer patientsScanlon, Brighid, Wyld, David, Roberts, Natasha, Durham, Jo and Toloo, Ghasem (Sam) (2023). Rethinking cancer prevention for migrant populations in Queensland, Australia: A retrospective cohort study comparing culturally and linguistically diverse and Australian born cancer patients. Global Public Health, 18 (1) 2202213, 1-13. doi: 10.1080/17441692.2023.2202213 |
|
2023 Journal Article Australasian consensus statement on the identification, prevention and management of hormonal crises in patients with neuroendocrine neoplasms (NENs) undergoing peptide receptor radionuclide therapy (PRRT)Li, Minmin, Chan, David L., Tapia Rico, Gonzalo, Cehic, Gabrielle, Lawrence, Ben, Wyld, David, Pattison, David A., Kong, Grace, Hicks, Rodney, Michael, Michael, Kiberu, Andrew Ddembe, Lim, Jennifer, Clifton-Bligh, Roderick, Tsang, Venessa, Roach, Paul J., Leyden, John, Diakos, Connie I., Price, Timothy J. and Pavlakis, Nick (2023). Australasian consensus statement on the identification, prevention and management of hormonal crises in patients with neuroendocrine neoplasms (NENs) undergoing peptide receptor radionuclide therapy (PRRT). Neuroendocrinology, 113 (3), 281-288. doi: 10.1159/000526848 |
|
2023 Conference Publication PRRT for control of hypoglycaemia and disease progression due to metastatic insulinomaPattison, D. A., Kong, G., Hofman, M. S., Akhurst, T., Ravi, Kumar A. S., Michael, M., Wyld, D., Burge, M., Chiang, C., Sachithanandan, N., Love, A. and Hicks, R. (2023). PRRT for control of hypoglycaemia and disease progression due to metastatic insulinoma. 20th Annual ENETs Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Electr Network, Mar 22-24, 2023. HOBOKEN: WILEY. |
